Background: In myasthenia gravis (MG) patients, the dysfunction of CD4
Conclusions: This subject will further reveal the role of IFN-γ in the pathogenesis of MG from a new perspective. It will also provide the scientific basis for the clinical targeted therapy of MG.
Background
Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness and chronic fatigue, which results from a blockage of the nerve impulse transmission from nerve endings to muscles by anti-acetylcholine receptor (AchR) antibodies at the neuromuscular junction. In 1895, the Germany doctor Jolly first officially named MG. But up till now, the exact etiology and pathogenesis of MG remain unclear. Therefore, it is key to explore the pathogenesis and search for the therapeutic targets of MG. And the results may suggest one important way to further overcome the other autoimmune diseases.
As the most important regulatory T cells, CD4 + CD25 + regulatory T cells (CD4 + CD25 + Tregs) were firstly defined by Sakaguchi in 1995 and they are characterized by expressing the chain of IL-2 receptor alpha (CD25) and fork head transcription factor 3 (FoxP3) [1] . CD4 + CD25 + Tregs can suppress the potential autoreactive T cells in a positive manner [1] and protect the body from CD4 + T cell-mediated autoimmune diseases [2] [3] [4] . Therefore, it suggests it is possible to find the targets that influence the attack of MG in regulatory T cells.
Previous studies once showed that the imbalance between Th1 and Th2 can result in MG. But with the discovery of CD4 + CD25 + Tregs, researchers had a new understanding about MG [5] . It is noted that in MG patients, if insufficient CD4 + CD25 + Tregs are produced to suppress the autoreactive T cells, the disease will be aggravated, while if the body can produce enough CD4 + CD25 + Tregs against their autoreactive T cells, the disease will be alleviated [6] . The experimental results showed that in the animal model of MG (experimental autoimmune myasthenia gravis, EAMG), the number of CD4 + CD25 + Tregs in CD4 + T spleen cells decreased and the expression of FoxP3 at mRNA level also decreased correspondingly [7] . The first part of our study mainly showed that the number of CD4 + CD25 + T cells in MG patients has no statistical difference from the number of healthy controls (HCs), but the function of them was seriously destroyed, which is consistent with the results of Luther and his colleagues.
At present, there is still inadequacy of previous research in explaining the molecular basis about the generation, 
CD25
− T cells from mice co-culture with IL-2, TGF-β, anti-CD3 and anti-CD28 antibodies can induce the expression of FoxP3 and make them obtain the regulating activity [12, 13] IFN-γ is regarded as a pro-inflammatory cytokine. However the question remains about the exact role of IFN-γ in EAMG. On one hand, it is not easy to make EAMG model for the mice lack of IFN-γ receptor. On the other hand, it is easier to build EAMG model in IFN-γ-deficient mice [14] . The paradoxical experimental evidence indicates that IFN-γ is a "double-edged sword". Different concentrations, micro environments or stages of immune responses lead to different effects. It promotes a Th1 response and T cell migration to the site of inflammation and amplifies an inflammatory cascade through its ability to mediate a variety of signaling events, causing the production of inflammatory molecules [15] . Moreover, the intensity of Th1-induced inflammation as quantifiable by the production of IFN-γ potentially triggers the immune system to call for a controlling mechanism.
Present study indicated that IFN-γ can induce CD4 + CD25 − T cells to CD4 + CD25 + Tregs in vitro in GBS patients [16] . MG is also an autoimmune disease as GBS and the function of CD4 +
− T cells has no difference between MG and GBS. Thus, in the second part of our study, we put forward and focus our study on the hypothesis " IFN-γ can induce CD4 
Methods

Patients and specimens
Twenty three patients (11 females and 12 males, aged 23-79 years) who met the criteria of MG were from the First Affiliated Hospital of Harbin Medical University during 2012 to 2014. Among them, ten patients were thymectomized at least 1 year because of thymic hyperplasia or thymoma, while other 13 patients have no abnormality of thymus. Prior to this study, all of the patients had not received the treatment of corticosteroids and other immunodepressants at least 1 year in advance to avoid any interference effects [17] . In addition, the patients with chronic-immune-mediated disorders or those who had received any immunomodulatory drugs within 3 months were excluded. The peripheral blood samples were obtained prior to the start of treatment. The characteristics of all the subjects are displayed in Table 1 . 19 healthy donors (ten females and nine males, aged 18-70 years) were included as healthy controls (HCs). Ethical approval for this study was granted by the Medical Ethics Review Board of the First Affiliated Hospital of Harbin Medical University and informed consent was obtained from every donor.
Isolation and purification of T-cell subsets
The peripheral blood mononuclear cells were separated by 
Monoclonal antibodies and flow cytometric analysis
Flow cytometric analysis was performed to quantify the induced CD4 + CD25 + T cells. Cells were stained with PerCPconjugated anti-CD4 (Clone: L200, BD Pharmingen), FITC-conjugated anti-CD25 (Clone: M-A251, BD Pharmingen) and PE-conjugated anti-FoxP3 (Clone: 206D, BD Pharmingen) respectively. Cells were stained with propidium iodide (PI, Sigma-aldrich) for nonviable cell exclusion prior to being analyzed on a FACS Calibur cytometerical (Becton Dickinson). Data processing was accomplished by CELLQuest software (BD). Cell viability measured by PI was always more than 98 % before stimulating and exceeded 95 % after stimulating.
Proliferation assay
Co-cultures were established in 96-well U-bottom plates incubated with 2 μg/ml anti-CD3 antibody. CD4 + T cells) × 100 %. The proliferation index (PI) was calculated using the formula: cpm after proliferation/ cpm before proliferation.
FoxP3 expression determined by real-time PCR
Foxp3 mRNA expression was quantified by real-time PCR using ABI PRISM 7700 Sequence Detector (Applied Biosystems). The human housekeeping gene β-Actin primers and probe set were used as the reference for sample normalization. Total RNA isolated from purified CD4 + CD25
+ T cell was reverse-transcribed into cDNA by using random hexamer primed. The primer set for Foxp3 was 5′-TTCGAAGAGCCAGAGGACTT-3′ and 5′-GCTGCT CCAGAGACTGTACC-3′. The probe for Foxp3 was 5′-FAM-CTCAAGCACTGCCAGGCGGACCATC-TAMRA-3′. The primer set for β-actin was 5′-ATCTGCTGGA AGGTGGACAGCGA-3′ and 5′-CCCAGCACAATGA AGATCAAGATCAT-3′. The probe for β-actin was 5′-FAM-TGAGCGCAAGTACTCCGTGTGGATCGGCG-TAMRA-3′(Invitrogen). The primers and probes used in the real-time PCR were ordered from Sangon (Shanghai, China) and designed not to amplify genomic DNA. Standard curves were generated from serial dilutions of purified plasmid DNA encoding the respective genes with a linear regression R greater than 0.99 and used to quantify mRNA copy numbers for each sample. The amplification protocol used was described as follows: 1 μl of synthesized cDNA product was subsequently added into PCR mix containing 25 μl of TaqMan 2 × PCR master mix (Applied Biosystems), 30 pmol human Foxp3 primer with 10 pmol probe, 2.5 μl β-Actin primer/probe set, and distilled water was added to make a total reaction volume of 50 μl. The PCR was programmed as an initial incubation for 10 min at 95°C followed by 40 thermal cycles of 15 s at 95°C and 1 min at 60°C. The normalized values in each sample were calculated as the relative quantity of Foxp3 mRNA expression divided by the relative quantity of β-Actin mRNA expression. All reactions were confirmed by at least one additional independent run [18] .
Statistical analysis
Data were expressed as mean ± SD. CD4 + CD25 − T cells, induced CD4
+ CD25 + T cells and nTregs were compared based on Bartlett's test for homogeneity of variances. ANOVA and t test were used. P < 0.05 was considered as statistically significant difference. + Tregs is 7.99 ± 1.92 % in thymectomized group, while it is 8.71 ± 2.11 % in non-thymectomized group. It can be found that there is no statistically significant difference between them (P > 0.05) (Fig. 2) . + T cells is nearly the same value. There is no statistical difference between them (Table 3) .
Results
Frequencies of CD4
The results of MG patients and HCs are compared with every given concentration of IFN-γ separately by t test. It shows that with the same concentration of IFN-γ, the percentage of the induced CD4 + CD25 + T cells from HCs varies from that of MG patients (P < 0.05). In particular, when the concentration of IFN-γ is 0 (only the anti-CD3 and anti-CD28 antibodies were added), the percentage of HCs also gives obviously higher value than that of MG patients. There is statistically considerable difference between them (P < 0.05).
The 23 MG patients details are shown in Table 1 As described before, the CD4 + T cells which express the higher level of CD25 as the induced CD4 + CD25 + T cells were selected [19] . But it should be noted that CD25 is not a specific marker of CD4 + CD25 + Tregs. For example, Hong J and Leonard C found in that effector CD4 + T cells, CD25 can also be detected [20] . FoxP3 is the most specific marker in comparison with the other markers. Thus, besides CD25, FoxP3 is also included in our experiment detection to further study whether the induced CD4 + CD25 + T cells are similar to nTregs phenotypically. Figure 4 shows the relationship between the FoxP3 expression of the induced CD4 + CD25 + T cells at mRNA level and the concentration of IFN-γ in MG patients. It can be found that IFN-γ is able to induce FoxP3 expression. Even though the concentration of IFN-γ is lower − T cells which is expressed as cpm (Fig. 5a ). The value of cpm decreases when the induced CD4 + T cells induced by 40 ng/ml IFN-γ have the most powerful suppressive function but it is still lower than the function of nTregs.
The suppressive percentage was shown in Fig. 5b . It can be seen that the suppressive percentage is parallel to the relative FoxP3 mRNA expression as IFN-γ concentration increases. So FoxP3 mRNA expression plays an + Tregs are altered in MG patients. The majority of MG patients are also associated with the changes in the thymus, like hyperplasia or thymoma. Thus, thymic ablation has been used as a common therapy for many MG patients. Although thymectomy usually leads to symptomatic benefit or remission, the mechanism by which still needs further exploration. In the first part of the experiment, we found that there was no statistical difference for the number of CD4 − T cells and anti-CD28 antibody provides a costimulatory signal in this process. Moreover, induction ration is associated with the concentration of IFN-γ. When the concentration of IFN-γ is 40 ng/ml, the ration reaches the peak. The possible reason is that IFN-γ is a "double-edged sword". It has regulatory and cytotoxic function. When the concentration of IFN-γ is between 20 and 40 ng/ml, it plays a regulatory role. Once it is above 40 ng/ml, it plays a cytotoxic role. In our study we show that 40 ng/ml IFN-γ has the most powerful ability to induce CD4 + Tregs. The questions raised above will be studied in our subsequent experiments. The results from different age stages are also compared and these results show rarely any statistical difference. But there are other factors such as the severity of MG, sex and the duration of disease involved, so it is desirable to perform further study in the future to examine the exact effect of age to the induction. + T cells in vitro and 40 ng/ml is the most appropriate concentration.
Our study provides the definitive evidence for IFN-γ inducing CD4 + CD25 − T cells to CD4 + CD25 + Tregs in MG patients in vitro. This subject will further reveal the role of IFN-γ in the pathogenesis of MG from a new perspective. It will also provide the scientific basis for the clinical targeted therapy of MG.
